FDA's policy statement for the development of new stereoisomeric drugs.
D000319:Adrenergic beta-Antagonists / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics; D000818:Animals; D001711:Biotransformation; D015195:Drug Design; D006801:Humans; D013237:Stereoisomerism; D014481:United States; D014486:United States Food and Drug Administration
D000319:Adrenergic beta-Antagonists